Author Details

Капланов, Камиль Даниялович

Issue Section Title File
Vol 10, No 4 (2008) Articles Rekomendatsii po obsledovaniyu i lecheniyu bol'nykh V-kletochnym khronicheskim limfoleykozom
Vol 16, No 2 (2014) Articles The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
Vol 21, No 4 (2019) CLINICAL ONCOLOGY The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
Vol 22, No 2 (2020) Guidelines Hodgkin's lymphoma PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas PDF
(Rus)
Vol 23, No 1 (2021) CLINICAL ONCOLOGY Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas PDF
(Rus)
Vol 23, No 2 (2021) CLINICAL ONCOLOGY The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review PDF
(Rus)
Vol 23, No 3 (2021) CLINICAL ONCOLOGY ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia PDF
(Rus)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies